Fund Update: 3,496,694 LAM RESEARCH (LRCX) shares added to BAILLIE GIFFORD & CO portfolio

Baillie Gifford & Co added 3,496,694 shares of Lam Research (LRCX) to their portfolio, according to an SEC 13F filing. Several institutional investors have recently adjusted their LRCX holdings, with notable increases from JPMorgan Chase, Invesco, and others. Analysts have set various price targets for LRCX, with a median of $402.0.

Original reporting
Published Nov 9, 2026, 11:41 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 12:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Fund Update: 3,496,694 LAM RESEARCH (LRCX) shares added to BAILLIE GIFFORD & CO portfolio — source image
Decision brief

The 30-second read

$LRCXBullishMed
01

Why it matters

The addition may lift LRCX modestly as investors interpret the fund's confidence, but the effect could be muted if the market has already priced in the buying.

02

Market read

Primary disclosure of a sizable new institutional holding; modest short‑term price influence expected.

03

What to watch

The filing does not disclose the fund's cost basis or timing of purchases, which could affect the actual market impact.

Relevance 7/10Novelty 7/10Timing: today

Background

13F filings disclose quarterly holdings of institutional managers. Baillie Gifford's new LRCX stake is the latest disclosed change.

Company-level read

Ticker impact

$LRCXBullishHigh confidence
Context

Baillie Gifford & Co added 3,496,694 shares of LRCX in its Q3 2026 13F filing, indicating a sizable new institutional stake.

Expected impact

modest upside as the market prices in the fresh institutional buying

Evidence & confidence

13F filings are primary source data; a $1.1 B addition from a respected fund can prompt buying pressure, especially if the fund has a history of long‑term holdings.

Market effects

Adds to the semiconductor equipment sector's institutional ownership, may be viewed as a vote of confidence for the industry.

U.S. market impact limited to LRCX; no broader regional effect.

Minimal global impact beyond the stock itself.

Counterpoint

The fund could be accumulating for a future sell‑off; large additions sometimes precede profit‑taking.

Key entities

  • Baillie Gifford & Co

    Asset manager that added a large LRCX position in its Q3 2026 filing.

  • Lam Research

    Semiconductor equipment maker (ticker LRCX) receiving the new institutional stake.

Related articles

$LRCXMedAI 8/10

BofA removes Lam Research, Micron, Nvidia from US 1 list

Bank of America removed Lam Research (LRCX), Micron (MU), and NVIDIA (NVDA) from its US 1 list, citing supply chain constraints and valuation adjustments. All three stocks retain Buy ratings. LRCX reported Q1 2027 revenue of $8.22B and EPS of $2.20, beating estimates, but analysts lowered price targets. The stock is down 24.6% over six months but up 33.6% year-over-year.

$AMATHighAI 8/10

Applied Materials Jumps 11% Ahead of Earnings; Lam Research Surges 9%, ASML Rises 6%

Applied Materials (AMAT) stock rose 11% to $370.81 ahead of its Q4 FY2026 earnings report, with revenue and EPS guidance provided. Lam Research (LRCX) and ASML (ASML) also surged 9% and 6% respectively, driven by AI demand and WFE spending projections. Analysts expect AMAT's EPS to grow 87.1% YoY and revenue 51.4% YoY. The companies' performance is linked to chipmaking equipment demand and AI-driven growth.

$LRCXMed

Lam Research Rallies Over Six Percent on Wall Street

Lam Research (LRCX) shares rose 6.46% to $213.39 on November 9, 2026, driven by institutional interest and a $25B share buyback program. B. Riley adjusted its price target to $310, maintaining a buy rating. Uncertainties remain due to high valuations and macroeconomic factors.